FDA Brief

Warning letters Drugs

FDA warning letter to

Dr Sankunni’s Ayurvedic Research Foundation Private Ltd.

LowIssued Apr 18, 2024Posted Apr 23, 2024Center for Drug Evaluation and Research | CDER

Dr Sankunni's Ayurvedic Research Foundation failed to correct drug listing and registration errors for its balms and hand sanitizer.

What happened

FDA reviewed the firm's drug listing information in its electronic Drug Registration and Listing System and found the firm listed as manufacturer for 12 balms and a hand sanitizer even though the firm confirmed in a December 15, 2022 records response that it does not manufacture these drugs. FDA asked on March 6, 2023 that the firm deregister and delist, but the listings were not corrected, and FDA also found listing errors including wrong dosage form, mismatched menthol strength, missing active ingredients, and incorrect label images.

What FDA found

  1. The firm did not meet its drug listing obligations, which is a prohibited act.

    section 510(j) of the FD&C Act, 21 U.S.C. 360(j); section 301(p), 21 U.S.C. 331(p)
  2. The firm stayed registered as a manufacturer and its listings named it as manufacturer even though it confirmed it does not manufacture the drugs.

    section 510(j)(1)(c) of the FD&C Act, 21 U.S.C. 360(j)(1)(c); 21 CFR 207.49(a)(12)(i)
  3. Some listings had incorrect dosage forms, mismatched menthol strength, a missing active ingredient, or incorrect label images.

    21 CFR 207.49(a)(6), 21 CFR 207.49(a)(4), and 21 CFR 207.49(a)(15)(ii)(B)
  4. Because the drugs were not properly listed, FDA treats them as misbranded.

    section 502(o) of the FD&C Act, 21 U.S.C. 352(o)
  5. Shipping such misbranded drugs in interstate commerce is prohibited.

    section 301(a) of the FD&C Act, 21 U.S.C. 331(a)

What FDA wants

FDA tells the company to respond in writing within 15 working days with the specific steps it has taken to correct the registration and listing violations and prevent recurrence, and to include related documentation. If it cannot finish in that time, it must explain why and give a completion date.

Who should pay attention

  • companies that rely on FDA's NDC Directory for billing, e-prescribing, or product lookup
  • firms using contract manufacturers that must list the correct manufacturing establishments
  • distributors and brands selling balms or hand sanitizers in the U.S.

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk
  2. InvaDerm, Inc.

    FDA says InvaDerm, Inc. of Somerset, NJ, markets unapproved new drugs without FDA-approved applications.

    High risk
  3. Aeroflex Industria de Aerosol Ltda.

    Brazil OTC drug maker Aeroflex ignored FDA records requests, prompting possible approval holds and US shipment refusals.

    High risk
  4. NSE Products, Inc. DBA Nu Skin Enterprises, Inc.

    FDA warns NSE Products (Nu Skin) over incomplete drug listing data for AP-24 products and 61 inactivated listings.

    Low